PUBLISHER: Transparency Market Research | PRODUCT CODE: 1322219

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1322219

Onco-hematology Molecular Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

PUBLISHED: June 5, 2023

PAGES: 179 Pages

DELIVERY TIME: 2-10 business days

SELECT AN OPTION

TMR's report on the global Onco-hematology Molecular Testing Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Onco-hematology Molecular Testing Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Onco-hematology Molecular Testing Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Onco-hematology Molecular Testing Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Onco-hematology Molecular Testing Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Onco-hematology Molecular Testing Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Onco-hematology Molecular Testing Market.

The report delves into the competitive landscape of the global Onco-hematology Molecular Testing Market. Key players operating in the global Onco-hematology Molecular Testing Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Onco-hematology Molecular Testing Market profiled in this report.

Key Questions Answered in Global Onco-hematology Molecular Testing Market Report:

What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
What are the opportunities in the global Onco-hematology Molecular Testing Market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Onco-hematology Molecular Testing Market - Research Objectives and Research Approach

The comprehensive report on the global Onco-hematology Molecular Testing Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Onco-hematology Molecular Testing Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Onco-hematology Molecular Testing .

Product Code: TMRGL85642

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Onco-hematology Molecular Testing Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Onco-hematology Molecular Testing Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Overview of Onco-hematology Molecular Testing Market
5.2. Key Product/ Brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry

6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 6.3.1. Chronic Myeloid Leukemia
  - 6.3.1.1. Polycythemia Vera
  - 6.3.1.2. Essential Thrombocythaemia
  - 6.3.1.3. Myelofibrosis
- 6.3.2. Myeloproliferative Neoplasms
- 6.3.3. Acute Myeloid Leukemia
- 6.3.4. Acute Lymphoblastic Leukemia
6.4. Market Attractiveness Analysis, by Blood Cancer Type

7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 7.3.1. BCR-ABL1 MBCR
- 7.3.2. JAK2
- 7.3.3. CALR
- 7.3.4. MPL
- 7.3.5. PML-RARA
- 7.3.6. NPM1
- 7.3.7. RUNX1-RUNX1T1
- 7.3.8. CBFB-MYH11
- 7.3.9. BCR-ABL1 mbcr
7.4. Market Attractiveness Analysis, by Blood Cancer Biomarker

8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technology, 2017-2031
- 8.3.1. qPCR
- 8.3.2. dPCR
- 8.3.3. Next-Generation Sequencing
- 8.3.4. Others
8.4. Market Attractiveness Analysis, by Technology

9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user

9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. National Reference Lab/Specialty Lab
- 9.3.2. University Hospital/Oncology Center
- 9.3.3. Community Hospital/IDN (Regional/National
9.4. Market Attractiveness Analysis, by End-user

10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region

11. North America Onco-hematology Molecular Testing Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 11.2.1. Chronic Myeloid Leukemia
  - 11.2.1.1. Polycythemia Vera
  - 11.2.1.2. Essential Thrombocythaemia
  - 11.2.1.3. Myelofibrosis
- 11.2.2. Myeloproliferative Neoplasms
- 11.2.3. Acute Myeloid Leukemia
- 11.2.4. Acute Lymphoblastic Leukemia
11.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 11.3.1. BCR-ABL1 MBCR
- 11.3.2. JAK2
- 11.3.3. CALR
- 11.3.4. MPL
- 11.3.5. PML-RARA
- 11.3.6. NPM1
- 11.3.7. RUNX1-RUNX1T1
- 11.3.8. CBFB-MYH11
- 11.3.9. BCR-ABL1 mbcr
11.4. Market Value Forecast, by Technology, 2017-2031
- 11.4.1. qPCR
- 11.4.2. dPCR
- 11.4.3. Next-Generation Sequencing
- 11.4.4. Others
11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. National Reference Lab/Specialty Lab
- 11.5.2. University Hospital/Oncology Center
- 11.5.3. Community Hospital/IDN (Regional/National
11.6. Market Value Forecast, by Country, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Blood Cancer Type
- 11.7.2. By Blood Cancer Biomarker
- 11.7.3. By Technology
- 11.7.4. By End-user
- 11.7.5. By Country

12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 12.2.1. Chronic Myeloid Leukemia
  - 12.2.1.1. Polycythemia Vera
  - 12.2.1.2. Essential Thrombocythaemia
  - 12.2.1.3. Myelofibrosis
- 12.2.2. Myeloproliferative Neoplasms
- 12.2.3. Acute Myeloid Leukemia
- 12.2.4. Acute Lymphoblastic Leukemia
12.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 12.3.1. BCR-ABL1 MBCR
- 12.3.2. JAK2
- 12.3.3. CALR
- 12.3.4. MPL
- 12.3.5. PML-RARA
- 12.3.6. NPM1
- 12.3.7. RUNX1-RUNX1T1
- 12.3.8. CBFB-MYH11
- 12.3.9. BCR-ABL1 mbcr
12.4. Market Value Forecast, by Technology, 2017-2031
- 12.4.1. qPCR
- 12.4.2. dPCR
- 12.4.3. Next-Generation Sequencing
- 12.4.4. Others
12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. National Reference Lab/Specialty Lab
- 12.5.2. University Hospital/Oncology Center
- 12.5.3. Community Hospital/IDN (Regional/National
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Blood Cancer Type
- 12.7.2. By Blood Cancer Biomarker
- 12.7.3. By Technology
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region

13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 13.2.1. Chronic Myeloid Leukemia
  - 13.2.1.1. Polycythemia Vera
  - 13.2.1.2. Essential Thrombocythaemia
  - 13.2.1.3. Myelofibrosis
- 13.2.2. Myeloproliferative Neoplasms
- 13.2.3. Acute Myeloid Leukemia
- 13.2.4. Acute Lymphoblastic Leukemia
13.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 13.3.1. BCR-ABL1 MBCR
- 13.3.2. JAK2
- 13.3.3. CALR
- 13.3.4. MPL
- 13.3.5. PML-RARA
- 13.3.6. NPM1
- 13.3.7. RUNX1-RUNX1T1
- 13.3.8. CBFB-MYH11
- 13.3.9. BCR-ABL1 mbcr
13.4. Market Value Forecast, by Technology, 2017-2031
- 13.4.1. qPCR
- 13.4.2. dPCR
- 13.4.3. Next-Generation Sequencing
- 13.4.4. Others
13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. National Reference Lab/Specialty Lab
- 13.5.2. University Hospital/Oncology Center
- 13.5.3. Community Hospital/IDN (Regional/National
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Blood Cancer Type
- 13.7.2. By Blood Cancer Biomarker
- 13.7.3. By Technology
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region

14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 14.2.1. Chronic Myeloid Leukemia
  - 14.2.1.1. Polycythemia Vera
  - 14.2.1.2. Essential Thrombocythaemia
  - 14.2.1.3. Myelofibrosis
- 14.2.2. Myeloproliferative Neoplasms
- 14.2.3. Acute Myeloid Leukemia
- 14.2.4. Acute Lymphoblastic Leukemia
14.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 14.3.1. BCR-ABL1 MBCR
- 14.3.2. JAK2
- 14.3.3. CALR
- 14.3.4. MPL
- 14.3.5. PML-RARA
- 14.3.6. NPM1
- 14.3.7. RUNX1-RUNX1T1
- 14.3.8. CBFB-MYH11
- 14.3.9. BCR-ABL1 mbcr
14.4. Market Value Forecast, by Technology, 2017-2031
- 14.4.1. qPCR
- 14.4.2. dPCR
- 14.4.3. Next-Generation Sequencing
- 14.4.4. Others
14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. National Reference Lab/Specialty Lab
- 14.5.2. University Hospital/Oncology Center
- 14.5.3. Community Hospital/IDN (Regional/National
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Blood Cancer Type
- 14.7.2. By Blood Cancer Biomarker
- 14.7.3. By Technology
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region

15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
- 15.2.1. Chronic Myeloid Leukemia
  - 15.2.1.1. Polycythemia Vera
  - 15.2.1.2. Essential Thrombocythaemia
  - 15.2.1.3. Myelofibrosis
- 15.2.2. Myeloproliferative Neoplasms
- 15.2.3. Acute Myeloid Leukemia
- 15.2.4. Acute Lymphoblastic Leukemia
15.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
- 15.3.1. BCR-ABL1 MBCR
- 15.3.2. JAK2
- 15.3.3. CALR
- 15.3.4. MPL
- 15.3.5. PML-RARA
- 15.3.6. NPM1
- 15.3.7. RUNX1-RUNX1T1
- 15.3.8. CBFB-MYH11
- 15.3.9. BCR-ABL1 mbcr
15.4. Market Value Forecast, by Technology, 2017-2031
- 15.4.1. qPCR
- 15.4.2. dPCR
- 15.4.3. Next-Generation Sequencing
- 15.4.4. Others
15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. National Reference Lab/Specialty Lab
- 15.5.2. University Hospital/Oncology Center
- 15.5.3. Community Hospital/IDN (Regional/National
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Blood Cancer Type
- 15.7.2. By Blood Cancer Biomarker
- 15.7.3. By Technology
- 15.7.4. By End-user
- 15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
- 16.3.1. Asuragen, Inc.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Bio-Rad Laboratories, Inc.
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. ICON plc
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. Invivoscribe, Inc.
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. QIAGEN N.V.
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Thermo Fisher Scientific, Inc.
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Cepheid
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Illumina, Inc.
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview

Product Code: TMRGL85642

List of Tables

Table 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 02: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 03: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 04: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 08: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 09: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 10: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 13: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 14: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 18: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 19: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 20: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 23: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 24: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 25: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
Table 28: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
Table 29: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 30: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

Figure 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Type, 2022
Figure 03: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Biomarker, 2022
Figure 04: Global Onco-hematology Molecular Testing Market Value Share, by Technology, 2022
Figure 05: Global Onco-hematology Molecular Testing Market Value Share, by End-user, 2022
Figure 06: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 07: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 08: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Chronic Myeloid Leukemia , 2017-2031
Figure 09: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Myeloproliferative Neoplasms, 2017-2031
Figure 10: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 11: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
Figure 12: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by BCR-ABL1 MBCR, 2017-2031
Figure 13: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by JAK2, 2017-2031
Figure 14: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Irreversible CALR, 2017-2031
Figure 15: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by MPL, 2017-2031
Figure 16: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Others, 2017-2031
Figure 17: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 18: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
Figure 19: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by QPCR , 2017-2031
Figure 20: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by DPCR, 2017-2031
Figure 21: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Next-Generation Sequencing, 2017-2031
Figure 22: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
Figure 23: Global Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 24: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 25: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by National Reference Lab/Specialty Lab, 2017-2031
Figure 26: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by University Hospital/Oncology Center, 2017-2031
Figure 27: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
Figure 28: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Region, 2022 and 2031
Figure 29: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Region, 2023-2031
Figure 30: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 31: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Country, 2022 and 2031
Figure 32: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country, 2023-2031
Figure 33: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 34: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 35: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 36: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
Figure 37: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 38: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
Figure 39: North America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 41: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 42: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 43: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 44: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 45: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 46: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 47: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
Figure 48: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 49: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
Figure 50: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 52: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 53: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 56: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 57: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 58: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
Figure 59: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 60: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
Figure 61: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 63: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 64: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 65: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 66: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 67: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 68: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 69: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker, 2023-2031
Figure 70: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 71: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
Figure 72: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 73: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 74: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 75: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 76: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 77: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
Figure 78: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
Figure 79: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
Figure 80: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
Figure 81: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
Figure 82: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Technology, 2023-2031
Figure 83: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 84: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 85: Global Onco-hematology Molecular Testing Market Share Analysis, by Company (2022)

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

Onco-hematology Molecular Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Description

Table of Contents

List of Tables

Onco-hematology Molecular Testing Market - Scope of Report

Key Questions Answered in Global Onco-hematology Molecular Testing Market Report:

Onco-hematology Molecular Testing Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Onco-hematology Molecular Testing Market

4. Market Overview

5. Key Insights

6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type

7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker

8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology

9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user

10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region

11. North America Onco-hematology Molecular Testing Market Analysis and Forecast

12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast

13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast

14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast

15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast

16. Competition Landscape

List of Tables

List of Figures